↓ Skip to main content

Flavokawain B, a kava chalcone, inhibits growth of human osteosarcoma cells through G2/M cell cycle arrest and apoptosis

Overview of attention for article published in Molecular Cancer, June 2013
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (88th percentile)
  • High Attention Score compared to outputs of the same age and source (91st percentile)

Mentioned by

news
1 news outlet
twitter
1 X user
facebook
6 Facebook pages
googleplus
1 Google+ user

Citations

dimensions_citation
72 Dimensions

Readers on

mendeley
42 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Flavokawain B, a kava chalcone, inhibits growth of human osteosarcoma cells through G2/M cell cycle arrest and apoptosis
Published in
Molecular Cancer, June 2013
DOI 10.1186/1476-4598-12-55
Pubmed ID
Authors

Tao Ji, Carol Lin, Lauren S Krill, Ramez Eskander, Yi Guo, Xiaolin Zi, Bang H Hoang

Abstract

Osteosarcoma (OS) is the most common primary bone malignancy with a high propensity for local invasion and distant metastasis. Limited by the severe toxicity of conventional agents, the therapeutic bottleneck of osteosarcoma still remains unconquered. Flavokawain B (FKB), a kava extract, has been reported to have significant anti-tumor effects on several carcinoma cell lines both in vitro and in vivo. Its efficacy and low toxicity profile make FKB a promising agent for use as a novel chemotherapeutic agent.

X Demographics

X Demographics

The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 42 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Spain 1 2%
India 1 2%
Unknown 40 95%

Demographic breakdown

Readers by professional status Count As %
Student > Master 9 21%
Student > Bachelor 7 17%
Researcher 5 12%
Professor > Associate Professor 4 10%
Student > Ph. D. Student 4 10%
Other 7 17%
Unknown 6 14%
Readers by discipline Count As %
Biochemistry, Genetics and Molecular Biology 10 24%
Agricultural and Biological Sciences 9 21%
Chemistry 5 12%
Pharmacology, Toxicology and Pharmaceutical Science 4 10%
Medicine and Dentistry 4 10%
Other 2 5%
Unknown 8 19%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 13. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 02 February 2023.
All research outputs
#2,482,536
of 23,580,560 outputs
Outputs from Molecular Cancer
#130
of 1,783 outputs
Outputs of similar age
#21,765
of 198,809 outputs
Outputs of similar age from Molecular Cancer
#2
of 12 outputs
Altmetric has tracked 23,580,560 research outputs across all sources so far. Compared to these this one has done well and is in the 89th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 1,783 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 6.0. This one has done particularly well, scoring higher than 92% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 198,809 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 88% of its contemporaries.
We're also able to compare this research output to 12 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 91% of its contemporaries.